Phathom Pharmaceuticals, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) is a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases. The company offers VOQUEZNA (vonoprazan), a potassium-competitive acid blocker (PCAB) approved for healing all grades of erosive esophagitis (EE), relieving heartburn in non-erosive gastroesophageal reflux disease (GERD), and as an H. pylori eradication regimen in combination with amoxicillin and clarithromycin or amoxicillin alone; VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK, which are co-packaged therapies for H. pylori infection; and VOQUEZNA TRIPLE 10 PAK, a new regimen launched to improve patient compliance through smaller pill sizes. Phathom operates primarily in the United States, with headquarters in Florham Park, New Jersey, and was founded in 2019 following the acquisition of assets from Takeda Pharmaceuticals. In recent developments, the company expanded its VOQUEZNA portfolio with the FDA approval and launch of VOQUEZNA TRIPLE 10 PAK in late 2024, enhancing treatment accessibility for H. pylori; entered a strategic collaboration with the National Heart, Lung, and Blood Institute (NHLBI) in 2025 to investigate vonoprazan's potential in pulmonary arterial hypertension; and reported positive Phase 3 topline results for vonoprazan in eosinophilic esophagitis (EoE) in mid-2025, positioning it as a potential first PCAB therapy in this indication. Phathom targets gastroenterologists, primary care physicians, and patients with acid-related disorders, operating within the specialty pharmaceuticals segment of the biopharma industry.
Phathom Pharmaceuticals, Inc. (PHAT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting
Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting
Phathom Pharmaceuticals, Inc. (PHAT) Q1 2026 Earnings Call Transcript
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue Estimates
Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives Consensus Rating of “Moderate Buy” from Analysts
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
Phathom Pharmaceuticals Upgraded by Barclays to Overweight With $18 Target
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives $22.25 Consensus PT from Brokerages
Phathom Pharmaceuticals, Inc. (PHAT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Phathom Pharmaceuticals, Inc. (PHAT) Q4 2025 Earnings Call Transcript
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q4 Loss, Beats Revenue Estimates
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026
Phathom Pharmaceuticals Pivots to GI Focus, Targets 2H 2026 Profitability, CEO Says at Guggenheim Summit
Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026